Biotech Values

[p3analyze]

I am serious - not that I am looking for argumentation at lunch time - an OBF boundary would give totally different interpretation than an ultra conservative one. Is it not a possibility that after the clinical hold, in an attempt to minimize impact of immature followup and save the bulk of alpha for final analysis. Can you imagine what will happen if Kirkman says only 0.001 was spent at this interim?